Fig. 1 · Structure
Documents & Downloads
Patritumab deruxtecan
ADC
Patritumab deruxtecan is an antibody-drug conjugate (ADC) that targets the HER3 receptor. It comprises a fully human anti-HER3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor via a cleavable tetrapeptide linker, enabling selective delivery of the cytotoxic payload. This compound demonstrates significant anticancer activity, making it a valuable tool for research in targeted cancer therapies and drug development.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2227102-46-5 |
| Applications | ADC |
| Molecular Weight | 155238 (average) |
| Synonyms | HER3-DXd; U3-1402 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.